title: Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
abstract: A study was undertaken to determine the effect chemotherapy had when used to treat 45 dogs with measurable metastatic osteosarcoma. The primary tumor was histologically confirmed as an osteosarcoma in each case. Thirty-nine dogs had the primary tumor surgically removed. Twenty-four of these dogs were treated adjunctively with cisplatin (70 mg/m2 of body surface, IV, q 3 weeks; median 2 doses, range 1 to 6 doses) prior to the onset of metastasis. The remaining 6 dogs from which the primary tumor was not surgically removed were diagnosed as having metastatic osteosarcoma in addition to the primary tumor on initial examination. The median time from initial examination until the development of metastatic disease was 115 days (range, 27 to 1,199 days). The location of the metastatic disease was lungs (31 dogs), bone (3 dogs), soft tissue (1 dog), and multiple sites including lungs, bone, and soft tissue sites (10 dogs). The metastatic lesions were confirmed by pretreatment biopsy (n = 8) or cytologic evaluation (n = 2) in 10 cases and at necropsy in 27 cases. The remaining 8 cases were diagnosed radiographically as multiple metastatic lesions in the lungs consistent with metastatic osteosarcoma. The metastatic disease was treated with cisplatin in 31 dogs (70 mg/m2, IV, q 3 weeks; median 2 doses, range 1 to 4 doses), doxorubicin in 11 dogs (30 mg/m2, IV, q 3 weeks; median 2 doses, range 1 to 3 doses), and mitoxantrone in 3 dogs (5 mg/m2, IV, q 3 weeks; median 2 doses, range 1 to 3 doses).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: R C
authors.initials: RC
authors.lastname: Straw
authors.forename: V J
authors.initials: VJ
authors.lastname: Jameson
authors.forename: L M
authors.initials: LM
authors.lastname: Walters
authors.forename: M H
authors.initials: MH
authors.lastname: Lafferty
authors.forename: B E
authors.initials: BE
authors.lastname: Powers
authors.forename: S J
authors.initials: SJ
authors.lastname: Withrow
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D012516:Osteosarcoma / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D012189:Retrospective Studies; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D008942:Mitoxantrone; D002945:Cisplatin